CN1038390C - Small-dose inactivated vaccine - Google Patents
Small-dose inactivated vaccine Download PDFInfo
- Publication number
- CN1038390C CN1038390C CN93103140A CN93103140A CN1038390C CN 1038390 C CN1038390 C CN 1038390C CN 93103140 A CN93103140 A CN 93103140A CN 93103140 A CN93103140 A CN 93103140A CN 1038390 C CN1038390 C CN 1038390C
- Authority
- CN
- China
- Prior art keywords
- present
- bacillus calmette
- guerin
- asthma
- guerin vaccine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Landscapes
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The present invention relates to a modified medicament using a bacillus calmette-guerin vaccine as a raw material. The small dose inactivated bacillus calmette-guerin vaccine of the present invention is an aqueous agent obtained by inactivating the bacillus calmette-guerin vaccine for inoculation, and the content of inactivated bacillus calmette-guerin is from 0.75 to 2 mg per milliliter. The present invention can achieve the goals of regulating and controlling the immunological functions of organisms by using a minimum dose, has no side effect, and can carry out long-term treatment for asthma and other diseases difficult to radically treat to achieve the goal of strengthening treatment effects; the short-term effective treatment rate of asthma in children, bronchitis and repeated upper respiratory tract infection can respectively reach 92.0%, 96.0% and 98.0%, and the long-term effective treatment rate of asthma in children can reach 91%; the present invention has the advantages of low price, convenient use, wide popularization in cities and countryside and great practical value.
Description
The present invention relates to a kind of medical drugs, particularly about make the improvement medicament of raw material with bacillus calmette-guerin vaccine.
Bacillus calmette-guerin vaccine is a bacillus tuberculosis bovis, is commissioned to train through more than 100 and supports the live vaccine that toxicity lowers, and is used for the tuberculosis prophylaxis inoculation, and effect duration is very short, and water preparation dosage form 1 month is promptly expired.General at present use freeze dried powder is extended the expiration date.Clinical usefulness bacillus calmette-guerin vaccine is before the deadline made intradermal injection, and the bacill calmette-guerin amount is 0.75 mg/ml, uses as improving antiphthisic immunity.Discover that bacillus calmette-guerin vaccine has the immunological adjuvant activity, the bacillus calmette-guerin vaccine of human deactivation is arranged, the bacill calmette-guerin amount is 75 mg/ml, and cut dispenser on the percutaneous improves immune function of human body.Local meeting produces redness, festers reactions such as microabscess after patient's medication.Patient can not adhere to medication, should not the longer course of treatment, do not reach therapeutic effect.
The present invention to provide a kind of novel be the medicament of raw material with the bacillus calmette-guerin vaccine, this medicament utilizes expired or is about to out of date bacillus calmette-guerin vaccine makes raw material, has reliable mediator's body immunity function, there is not the effect of paying, energy long period medication improves curative effect, the acceptable characteristics of patient.
The present invention is a kind of inactivated vaccine compositions, and by the water preparation that inoculation obtains after deactivation with bacillus calmette-guerin vaccine, every milliliter contains deactivation bacill calmette-guerin amount is 0.75～2 milligram.
What the present invention was different with existing medicament is to have adopted small-dose inactivated vaccine, also uses low dose now, but without deactivation, is specificity, and as the tuberculosis prophylaxis inoculation, this medicament is used for intradermal injection.The bacillus calmette-guerin vaccine of deactivation also has the human mistake, but dosage is big, is 37.5 times to 100 times of the present invention, and the effect of paying is big, is used for scarification.
The present invention is on probation through animal and human body, finds a kind of minimum dose to reach the medicament of therapeutic effect.It mainly acts on is to stimulate monokaryon one macrophage and T cell, and the B cell is had potentiation, also can strengthen the function of NK cell.The present invention adopts the technical characterictic of inactivated vaccine, and the utilization rate of bacillus calmette-guerin vaccine is greatly improved, and provides new purposes for being considered as out of date medicine originally.The present invention adopts low dose of technical characterictic, has both guaranteed curative effect, can reduce the effect of paying again, or does not have the effect of paying, and can extend the period of treatment, and can carry out the treatment of long period to the disease of refractory such as asthma, reaches the purpose of consolidating curative effect.In addition, the present invention makes easy to use, and is inexpensive, can extensively promote in town and country, has practical value.
Below the invention will be further described with embodiment.
The embodiment raw material: the lyophilized bacillus calmette-guerin vaccine powder that the Shanghai biological study is produced, out of date or be about to out of dately all can.
The embodiment manufacture method: under aseptic condition, the lyophilized bacillus calmette-guerin vaccine powder is even with physiological saline solution, and every milliliter contains 0.75 milligram in the packing ampoule, or 0.85 milligram, or 0.95 milligram or 1.10 milligrams, or 1.20 milligrams, or 1.30 milligrams, or 1.40 milligrams, or 1.50 milligrams, or 1.60 milligrams, or 1.70 milligrams, or 1.80 milligrams, or 1.90 milligrams, or 2.0 milligrams tulase.Install the envelope small jar, place 6.0 ℃ of water bath deactivations, take out after 60 minutes, place in the cryogenic refrigerator and preserve, standby.
Product standard: the water preparation after the deactivation is done tulase and is cultivated, no tulase growth.
Embodiment using method: get 0.1 milliliter of finished product, drop under the preceding facies medialis brachii
The district, three of children's's scarifications are grown up four, and every is about 1 centimetre, and cut is not hemorrhage to be degree, natural drying, red line appears in the part.Weekly the treatment time, 10 times is a course of treatment ,-as carry out 1～2 course of treatment.But strengthen treatment in order to consolidate the curative effect proper extension course of treatment or good morbidity season.
Rabbit test method and result: make 2O Japan large ear rabbit of immunologic hypofunction with cyclophosphamide, and be divided into two groups with random table, one group gives embodiment finished product injection for curing, and another spider is given any treatment.Treatment group lymhocyte transformation rate improves, and the reaction of PHA skin test blush increases, and lymphocyte absolute value increases.Two groups relatively, difference highly significant (the P value is all less than 0.01).
Scarification of the present invention is used in infantile asthma 252 examples, bronchitis 52 examples, and repetitive upper respiratory tract infection 70 examples have effectively been regulated body's immunity, and patient symptom alleviates, and frequency of disease development reduces or recovery from illness.Effective percentage is respectively 92.0%, 98.0%, 98.0% in the recent period, does not see any pair of reaction.Before and after the treatment, measure through multiple immune indexes, the result is treatment back I
gG, I
gA is significantly improved, and PHA skin test reaction blush enlarges RBCC
3bReceptor active increases, and prompting treatment back cellular immunization and humoral immune function all have enhancing.Infantile asthma 151 examples were observed 5 years, and late result cures 61%, takes a turn for the better 30%, total effective rate 91%.
The present invention also can be used for treating the asthma bronchitis of growing up, senile chronic bronchitis, hepatitis B, allergic rhinitis, urticaria, immunologic function disequilibriums such as malignant tumor postoperative and the immune disease relevant with immunity.
Claims (1)
1, inactivated vaccine compositions, by the water preparation that inoculation obtains after deactivation with bacillus calmette-guerin vaccine, every milliliter contains deactivation bacill calmette-guerin amount is 0.75～2 milligram.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN93103140A CN1038390C (en) | 1993-03-20 | 1993-03-20 | Small-dose inactivated vaccine |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN93103140A CN1038390C (en) | 1993-03-20 | 1993-03-20 | Small-dose inactivated vaccine |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1080189A CN1080189A (en) | 1994-01-05 |
| CN1038390C true CN1038390C (en) | 1998-05-20 |
Family
ID=4984485
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN93103140A Expired - Fee Related CN1038390C (en) | 1993-03-20 | 1993-03-20 | Small-dose inactivated vaccine |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1038390C (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101069743B (en) * | 2004-07-27 | 2011-04-06 | 张锦铭 | Use of inactive BCG vaccine in preparation of use for treatment of allergic action diseases |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2438690B1 (en) * | 2012-06-15 | 2015-01-16 | Fundació Institut Per A La Investigació En Ciències De La Salut "Germans Trias I Pujol" (Igtp) Unitat De Tuberculosi Experimental | Inactivated mycobacteria for oral use in the prevention of tuberculosis |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4152423A (en) * | 1971-11-19 | 1979-05-01 | Agence Nationale De Valorisation De La Recherche (Anvar) | Immunological agents |
| WO1992008484A1 (en) * | 1990-11-08 | 1992-05-29 | University College London | Mycobacterium vaccae in the treatment of uveitis |
-
1993
- 1993-03-20 CN CN93103140A patent/CN1038390C/en not_active Expired - Fee Related
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4152423A (en) * | 1971-11-19 | 1979-05-01 | Agence Nationale De Valorisation De La Recherche (Anvar) | Immunological agents |
| WO1992008484A1 (en) * | 1990-11-08 | 1992-05-29 | University College London | Mycobacterium vaccae in the treatment of uveitis |
Non-Patent Citations (3)
| Title |
|---|
| CAN.MED.ASSOC.J.,(1987)136/4 1987.1.1 ENDOBRONCHIAL TUBER-CNLOSIS IN AN ASIAN MAN VALCINATED WITH B C G * |
| CAN.MED.ASSOC.J.,(1987)136/4 1987.1.1 ENDOBRONCHIAL TUBER-CNLOSIS IN AN ASIAN MAN VALCINATED WITH B C G;中国实用儿科杂志 1993.8.1 小剂量灭活卡介苗治疗小儿哮喘支气管炎，上呼吸通感染，张锦铭 * |
| 中国实用儿科杂志 1993.8.1 小剂量灭活卡介苗治疗小儿哮喘支气管炎，上呼吸通感染，张锦铭 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101069743B (en) * | 2004-07-27 | 2011-04-06 | 张锦铭 | Use of inactive BCG vaccine in preparation of use for treatment of allergic action diseases |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1080189A (en) | 1994-01-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102836367B (en) | Bacteria-resisting, inflammation-diminishing and itching-relieving traditional Chinese medicine composition and preparation method and application thereof | |
| CN1057445C (en) | Method for preparing anticancer bioactive peptide preparation | |
| CN1471952A (en) | Preparation for Chinese medicine multiple fungus mixed fermenting oral liquid and producing process thereof | |
| CN106362125A (en) | Health-care foot patch and application method thereof | |
| CN1038390C (en) | Small-dose inactivated vaccine | |
| CN101475920B (en) | Preparation method of Bacillus pumilus for treating burn and metabolite | |
| CN1772007A (en) | Fermented aweto hypha tablet | |
| CN102727581A (en) | Pharmaceutical composition with wound repairing effect | |
| CN100490829C (en) | Selenium-rich hedgehog fungus extract preparation for treating colitis, gastritis and stomach cancer and its preparing process | |
| CN101069743B (en) | Use of inactive BCG vaccine in preparation of use for treatment of allergic action diseases | |
| CN107468715A (en) | Bacillus cercus CGMCC0601 zymotic fluids are preparing the application in treating diabetes trauma Wound medicine | |
| CN101676401B (en) | Scorpion extract | |
| CN102178915A (en) | Hair growing fluid | |
| CN105125639A (en) | Traditional Chinese medicine composition for preventing and treating mastitis of dairy cattle | |
| WO2020139308A1 (en) | Inactivated staphylococcal liquid vaccine | |
| CN110384748A (en) | A kind of weapons wound badu shengji powder | |
| CN1836569A (en) | Human body nutritious regulator and method for making same and uses | |
| CN116042490B (en) | Composite probiotics for resisting fatigue and improving exercise capacity as well as preparation method and application thereof | |
| CN1602956A (en) | Deactivated BCG for treating disease | |
| CN104146156B (en) | The sick feed addictive of control Bordetella Bronchiseptica of Rabbit and application thereof | |
| CN117247976B (en) | Preparation of kuh-seng fermentation extract and application of kuh-seng fermentation extract in efficacy type oral care products | |
| CN1098293A (en) | Scorpion venom injection and method for making thereof and usage | |
| CN101791318B (en) | Novel application of bacterial lipopolysaccharides | |
| CN100443099C (en) | Antibiotic anti-inflammatory medical-herb stuffed pillows, and preparation method | |
| CN1281894A (en) | Method for transferring human endostatin gene lactic bacteria, its product and application |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C06 | Publication | ||
| PB01 | Publication | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C17 | Cessation of patent right | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 19980520 Termination date: 20110320 |